The rise of superbugs, or multidrug-resistant bacteria, poses a severe threat to global health and modern medicine. These bacteria have developed resistance to multiple antimicrobial drugs, making traditional treatments ineffective. The misuse and overuse of antibiotics in humans, animals, and agriculture have accelerated the emergence of superbugs, creating a complex and alarming public health crisis. Superbugs can cause severe infections that are challenging to treat, leading to increased morbidity and mortality rates. In hospitals, healthcare-associated infections involving superbugs are a significant concern, as these facilities can serve as breeding grounds for resistant strains. The spread of superbugs is not confined by borders; it transcends geographical boundaries, making it a global issue that requires coordinated efforts for containment. In response to the growing threat of superbugs, researchers and pharmaceutical companies are actively exploring innovative approaches to develop superdrugs—potent antimicrobial agents capable of combating multidrug-resistant bacteria. The conventional model of antibiotic development faces challenges, and scientists are exploring alternative strategies to discover and design effective drugs. One promising avenue is the development of bacteriophage therapy, which utilizes viruses that target and destroy specific bacteria. This approach offers a precision medicine solution, as bacteriophages can be tailored to combat particular strains of superbugs. Nanotechnology is another frontier, with researchers exploring nanoparticles and nanomaterials to deliver antimicrobial agents more effectively and reduce the development of resistance.